ProShare Advisors LLC Increases Position in Hologic, Inc. (NASDAQ:HOLX)

ProShare Advisors LLC lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,529 shares of the medical equipment provider’s stock after purchasing an additional 2,225 shares during the period. ProShare Advisors LLC’s holdings in Hologic were worth $2,935,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of HOLX. Price T Rowe Associates Inc. MD increased its stake in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after purchasing an additional 2,753,016 shares during the last quarter. Black Creek Investment Management Inc. grew its position in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after buying an additional 885,524 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Hologic by 5.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock worth $172,780,000 after acquiring an additional 124,739 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Hologic by 4.0% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after acquiring an additional 87,176 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Hologic by 117.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after acquiring an additional 1,168,564 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.3 %

Shares of HOLX stock opened at $80.10 on Friday. The business’s fifty day moving average price is $81.02 and its 200 day moving average price is $77.24. The firm has a market capitalization of $18.69 billion, a PE ratio of 40.87, a P/E/G ratio of 2.58 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.93 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insider Activity

In related news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the transaction, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. In the last three months, insiders sold 18,280 shares of company stock worth $1,469,973. Company insiders own 1.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HOLX. Evercore ISI boosted their target price on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Tuesday, July 30th. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday, September 17th. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday. Finally, JPMorgan Chase & Co. raised their price objective on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Hologic has an average rating of “Moderate Buy” and an average target price of $87.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.